Medicare Drug Plan Costs Set to Rise as Federal Subsidy Program Ends
A temporary fix that kept standalone Part D premiums stable is expiring, potentially leaving seniors with higher out-of-pocket expenses in 2027.
The direct answer
The conventional wisdom often suggests that Medicare prescription drug costs are a predictable expense for seniors. However, a federal demonstration program designed to stabilize standalone Medicare Part D premiums is set to conclude at the end of 2024
"Additionally, CMS is announcing the conclusion of the Part D Premium Stabilization Demonstration, a voluntary demonstration for standalone prescription drug plans implemented in CY 2025 to address volatility and variation in standalone premiums following benefit changes mandated by the Inflation Reduction Act (IRA)."
. This program, implemented after benefit changes mandated by the Inflation Reduction Act (IRA), provided temporary subsidies to cushion the impact on beneficiaries of standalone prescription drug plans
"Without these extra subsidies in place for 2027, some Part D stand-alone drug plan enrollees could face a larger premium increase for drug coverage next year than in recent years, though plan-specific premium amounts are not yet known."
. With its expiration, seniors could see "noticeably more expensive" Part D plans starting in contract year 2027
"Without these extra subsidies in place for 2027, some Part D stand-alone drug plan enrollees could face a larger premium increase for drug coverage next year than in recent years, though plan-specific premium amounts are not yet known."
. While CMS finalized policies for 2027 that include a 2.48% average increase in Medicare Advantage payments
$UNH , $HUM , and $OSCR shares are trading higher after CMS finalized a 2.48% average increase in 2027 Medicare Advantage payments, above expectation. https://t.co/0Z0Mf28Abh
— Wall St Engine link
, the conclusion of the Part D Premium Stabilization Demonstration is a separate development that directly impacts standalone drug plans. This shift means the market may not have the same buffer against premium volatility, leading to potentially higher costs for millions of enrollees who rely on these specific drug coverage options
"Without these extra subsidies in place for 2027, some Part D stand-alone drug plan enrollees could face a larger premium increase for drug coverage next year than in recent years, though plan-specific premium amounts are not yet known."
.
The End of a Temporary Lifeline
For the past few years, a federal demonstration program has quietly kept standalone Medicare Part D premiums from fluctuating wildly. Implemented in 2025, this voluntary initiative aimed to smooth out premium variations that arose after changes mandated by the Inflation Reduction Act
"Additionally, CMS is announcing the conclusion of the Part D Premium Stabilization Demonstration, a voluntary demonstration for standalone prescription drug plans implemented in CY 2025 to address volatility and variation in standalone premiums following benefit changes mandated by the Inflation Reduction Act (IRA)."
. Essentially, it acted as a temporary subsidy, absorbing some of the market's volatility. Now, this program is concluding at the end of 2024, meaning the safety net for these specific drug plans is being removed
"Additionally, CMS is announcing the conclusion of the Part D Premium Stabilization Demonstration, a voluntary demonstration for standalone prescription drug plans implemented in CY 2025 to address volatility and variation in standalone premiums following benefit changes mandated by the Inflation Reduction Act (IRA)."
. This isn't about general Medicare Advantage payment rates, which saw a finalized 2.48% average increase for 2027
$UNH , $HUM , and $OSCR shares are trading higher after CMS finalized a 2.48% average increase in 2027 Medicare Advantage payments, above expectation. https://t.co/0Z0Mf28Abh
— Wall St Engine link
, but a distinct policy shift impacting beneficiaries of standalone Part D plans. The lack of these extra subsidies in 2027 could mean "larger premium increases for some Part D stand-alone drug plan enrollees" than they've experienced recently
"Without these extra subsidies in place for 2027, some Part D stand-alone drug plan enrollees could face a larger premium increase for drug coverage next year than in recent years, though plan-specific premium amounts are not yet known."
.
Market 'Stabilization' or Just Higher Premiums?
The language surrounding these policy changes often sounds reassuring. CMS stated it is "stabilizing the market so this bailout is no longer needed," according to remarks associated with the program's earlier phases
"We are stabilizing the market so this bailout is no longer needed."
. However, for seniors enrolled in standalone Part D plans, the end of the stabilization demonstration could feel less like market healing and more like a direct hit to their wallets. The voluntary nature of the demonstration meant it wasn't universally applied, but its conclusion removes a buffer that helped manage premium costs. Without this temporary measure, the underlying cost pressures or market uncertainties that necessitated the program in the first place may re-emerge, leading to "noticeably more expensive" plans in 2027
"Without these extra subsidies in place for 2027, some Part D stand-alone drug plan enrollees could face a larger premium increase for drug coverage next year than in recent years, though plan-specific premium amounts are not yet known."
.
What This Means for Your 2027 Drug Coverage
While the exact premium increases for 2027 are not yet finalized and will vary by plan and region, the expiration of the stabilization program is a significant factor. Beneficiaries of standalone Part D plans should anticipate potentially higher costs than they might have expected if the program had continued. This isn't a guaranteed massive hike for everyone, but the "extra subsidies" that helped keep premiums down are gone
"Without these extra subsidies in place for 2027, some Part D stand-alone drug plan enrollees could face a larger premium increase for drug coverage next year than in recent years, though plan-specific premium amounts are not yet known."
. The Centers for Medicare & Medicaid Services (CMS) has released information on the National Average Monthly Bid Amount for Part D, which serves as a benchmark, but the conclusion of the stabilization demonstration is a separate, crucial element affecting the final price seniors will pay
"Additionally, CMS is announcing the conclusion of the Part D Premium Stabilization Demonstration, a voluntary demonstration for standalone prescription drug plans implemented in CY 2025 to address volatility and variation in standalone premiums following benefit changes mandated by the Inflation Reduction Act (IRA)."
. Be prepared to scrutinize your plan options closely during the next enrollment period.
Common mistakes
- Assuming all Medicare drug costs are stable.
The conventional narrative often overlooks specific federal programs designed to temporarily stabilize costs, like the Part D Premium Stabilization Demonstration, whose expiration directly impacts out-of-pocket expenses. - Focusing solely on Medicare Advantage payment rates.
While CMS released 2027 rates for Medicare Advantage [c3], the ending of the Part D Premium Stabilization Demonstration is a separate and critical issue for beneficiaries of standalone Part D plans. - Ignoring the impact of the Inflation Reduction Act.
The IRA's benefit changes necessitated the stabilization program in the first place [c5, c6]; its conclusion is a direct consequence of those earlier legislative actions and their subsequent market adjustments.
"We are stabilizing the market so this bailout is no longer needed."
. This leaves seniors vulnerable to premium increases that were temporarily masked, turning a perceived stable cost into a potential financial burden next year.
Frequently asked
What is the Part D Premium Stabilization Demonstration?
It was a voluntary federal program implemented in 2025 to address and reduce volatility in standalone Medicare Part D prescription drug plan premiums, particularly following benefit changes mandated by the Inflation Reduction Act. It provided temporary subsidies to help keep costs stable for beneficiaries.
When does this program end?
The demonstration program is set to conclude at the end of 2024. This means its stabilizing effects will no longer be in place for the 2027 contract year.
Will my Medicare Part D costs definitely increase in 2027?
While not guaranteed for every individual, the expiration of the stabilization program removes a key factor that has been suppressing premium increases. Seniors enrolled in standalone Part D plans should anticipate potentially higher costs and be prepared to review their plan options carefully.
Sources
More from Healthcare Policy → · Back to Perch · Browse all stories